A fund reduced its stake in MAZE by 70,503 shares, trimming holdings to 99,850 shares worth $2.98 million.
HighVista Strategies sold 70,503 shares of Maze Therapeutics (NASDAQ:MAZE) in Q1 2026, valued at approximately $3.11 million based on the quarter’s average closing price. The sale reduced the fund’s position to 99,850 shares, currently worth $2.98 million.
Maze Therapeutics stock has surged 180% over the past year, outperforming the S&P 500’s 25% gain in the same period. The company focuses on precision medicines for renal, cardiovascular, and metabolic diseases, with lead programs in Phase I and II trials.
Following the sale, MAZE accounted for 0.82% of HighVista’s reported assets under management. The fund’s top holdings include DBC ($30.61 million), ABVX ($12.61 million), and PRAX ($8.48 million). Shares closed at $26.43 on May 14, 2026.